炎症性腸疾患の患者からのコンメンサル微生物群は,遺伝子毒性代謝産物を生成する.
PubMedで要約を見る
まとめ
この要約は機械生成です。腸内微生物は,大腸がん (CRC) に関連する遺伝子毒性化学物質を生成します. 研究者らは,CRCの潜在的寄生体であるバクテリアのモルガネラモルガニから インドリミンというDNAを損傷する新しい化合物を発見しました.
科学分野
- 微生物学
- 遺伝学
- 腫瘍学
背景
- 微生物から派生した代謝物はDNA損傷を引き起こし,大腸がん (CRC) に寄与する.
- 腸内微生物によって生成される 遺伝子毒性化学物質の全範囲は 完全に理解されていません
- 炎症性腸疾患 (IBD) の患者はゲノトキシンを生成する腸内微生物を抱えています
研究 の 目的
- 腸内共生細菌の遺伝子毒性を体系的に評価する.
- 腸内微生物群によって生成される新しい遺伝子毒性代謝物質を特定する.
- 特定の遺伝子毒素が結腸直腸がんに 与える影響を調査する.
主な方法
- ゲノム毒性を検知するパイプラインを開発した.
- IBD患者の腸内微生物を採取して分析した.
- バクテリアの遺伝学を使って ミュータントを作り 遺伝子毒素の産生を評価した
- 微生物の遺伝子毒素がマウスモデルで結腸腫瘍形成に与える影響を評価した.
主要な成果
- 遺伝子に毒性のある代謝産物を生成する 多様な遺伝子集団の腸内微生物を特定した.
- モルガネラ・モルガニーによって産生される インドリミンと呼ばれる 遺伝子毒の新種を発見した
- インドリミンを生成できない*M. morganii*変異体は遺伝子毒性を示せず,マウスの結腸腫瘍を悪化させなかった.
結論
- 腸内微生物群には 未知の遺伝子毒性小分子が 存在します
- モルガネラ・モルガニー (Morganella morganii) によって生成されるインドリミンは,CRCに寄与する新種の遺伝子毒素である.
- これらの発見は,宿主の健康と病気に対する微生物の遺伝子毒素の潜在的な影響を強調しています.
関連する概念動画
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

